Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31510752 | 1.00 | KDM4E (0.34) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL29483238 | 0.86 | CHRNB2 (0.33) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL31448643 | 0.80 | — | — | |
| SCHEMBL1404442 | 0.78 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL21808534 | 0.78 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL3174694 | 0.78 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL6336086 | 0.76 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL31275868 | 0.76 | NOS2 (0.32) | NOS2OPRM1 | |
| SCHEMBL2302714 | 0.76 | CHRNB2 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL16178433 | 0.76 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4188924-B1 | ANTAGONIST COMPOUNDS | ADORX THERAPEUTICS LTD (GB) | 2025-06-18 | — | — | EP | claimed |
| EP-4452246-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-10-30 | — | — | EP | claimed |
| EP-4452264-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-10-30 | — | — | EP | claimed |
| WO-2023118126-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | claimed |
| WO-2023118102-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| EP-2268646-A2 | THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2011-01-05 | — | — | EP | claimed |
| WO-2009126806-A2 | THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-15 | — | — | WO | claimed |
| US-12473301-B2 | Isoquinoline compounds for the treatment of cancer | GENENTECH, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-3860995-B1 | ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2025-04-16 | — | — | EP | disclosed |
| EP-3487856-B1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | BAYER AG (DE) | 2025-01-22 | — | — | EP | disclosed |
| CN-113135896-B | Methylpyrazole derivatives as RET inhibitors | 正大天晴药业集团股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| EP-4452263-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A P2X3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-10-30 | — | — | EP | disclosed |
| EP-4452264-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-10-30 | — | — | EP | disclosed |
| WO-2016027195-A1 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | PFIZER INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| US-8357684-B2 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-22 | — | — | US | disclosed |
| US-20110190503-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICAL NV | 2011-08-04 | — | — | US | disclosed |
| US-20110159563-A1 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICAL NV | 2011-06-30 | — | — | US | disclosed |
| US-7939527-B2 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-10 | — | — | US | disclosed |
| US-20090258854-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473301-B2 | Isoquinoline compounds for the treatment of cancer | PGK1, PHKG1, NEK1 | KDM4E 1246/4885MAPT 4365/4885KMT2A 737/4885 |
| US-20090258854-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R2 | KDM4E 1122/4885MAPT 2667/4885KMT2A 1674/4885 |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | KDM4E 1158/4885MAPT 1506/4885KMT2A 682/4885 |
| US-20110159563-A1 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R2 | KDM4E 722/4885MAPT 3185/4885KMT2A 1664/4885 |
| US-20110190503-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R2 | KDM4E 1122/4885MAPT 2667/4885KMT2A 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.